ARPINO, GRAZIA
ARPINO, GRAZIA
Dipartimento di Medicina clinica e Chirurgia
Treatment of triple negative brest cancer (TNBC): current options and future perspectives.
2010 DE LAURENTIIS, Michelino; Cianniello, Daniela; Caputo, Roberta; Stanzione, Brigida; Arpino, Grazia; Cinieri, S; Lorusso, V; DE PLACIDO, Sabino
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY.
2002 Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino
Prognostic and predictive factors in breast cancer, an evidence-based medicine approach
2002 Mohsin, Sk; Bardou, Vj; Arpino, Grazia; Chamness, Gc; Allred, Dc
Capitolo 4 - Terapia Medica
2011 G., Tortora; F., Ciardiello; Arpino, Grazia; A. R., Bianco
GMO-Gestione Malattie Oncologiche in Regione Campania.
2011 Arpino, Grazia; Simona, Cammarota; DE ANGELIS, Carmine; Claudia, Pizzi; Vincenzo, Perone; Giuseppina, Tommasielli; Giovanni, Arpino; Novellino, Ettore; DE PLACIDO, Sabino
Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes
2005 Arpino, Grazia; H., Weiss; R., Elledge
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases.
2001 Francesco, Cognetti; Arpino, Grazia; DE LAURENTIIS, Michelino; Paola, Papaldo; Chiara, Sguotti; Modesto, D'Aprile; Francesco, Recchia; DE PLACIDO, Sabino; Angelo Raffaele, Bianco
A metanalysis of interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)”,
2000 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; C., Carlomagno; F., Ciardiello; G., Tortora; Ar, Bianco; DE PLACIDO, Sabino
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance
2003 Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge
Triple-negative breast cancers: Biomarkers and outcomes
2010 Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia
Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer
2002 Arpino, Grazia; Nair Krishnan, M; Doval Dinesh, C; V. J., Bardou; G., Clark; R., Elledge
Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition.
2004 Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R.
HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study
2002 Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge
The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy.
2003 Arpino, Grazia; H., Weiss; S., Hilsenbeck; K., Osborne
Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy.
2002 V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark
Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance.
2004 Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm
Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts.
2006 M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff
Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer
2003 Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies
2002 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M.
Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
---|---|---|---|---|
Treatment of triple negative brest cancer (TNBC): current options and future perspectives. | 1.1 Articolo in rivista | 2010 | DE LAURENTIIS, Michelino; Cianniello, Daniela; Caputo, Roberta; Stanzione, Brigida; Arpino, Grazia; Cinieri, S; Lorusso, V; DE PLACIDO, Sabino | |
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY. | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino | |
Prognostic and predictive factors in breast cancer, an evidence-based medicine approach | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Mohsin, Sk; Bardou, Vj; Arpino, Grazia; Chamness, Gc; Allred, Dc | |
Capitolo 4 - Terapia Medica | 2.1 Contributo in volume (Capitolo o Saggio) | 2011 | G., Tortora; F., Ciardiello; Arpino, Grazia; A. R., Bianco | |
GMO-Gestione Malattie Oncologiche in Regione Campania. | 2.1 Contributo in volume (Capitolo o Saggio) | 2011 | Arpino, Grazia; Simona, Cammarota; DE ANGELIS, Carmine; Claudia, Pizzi; Vincenzo, Perone; Giuseppina, Tommasielli; Giovanni, Arpino; Novellino, Ettore; DE PLACIDO, Sabino | |
Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes | 4.1 Articoli in Atti di convegno | 2005 | Arpino, Grazia; H., Weiss; R., Elledge | |
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. | 4.1 Articoli in Atti di convegno | 2001 | Francesco, Cognetti; Arpino, Grazia; DE LAURENTIIS, Michelino; Paola, Papaldo; Chiara, Sguotti; Modesto, D'Aprile; Francesco, Recchia; DE PLACIDO, Sabino; Angelo Raffaele, Bianco | |
A metanalysis of interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)”, | 8.02 Comunicazioni a Convegni o Seminari | 2000 | DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; C., Carlomagno; F., Ciardiello; G., Tortora; Ar, Bianco; DE PLACIDO, Sabino | |
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge | |
Triple-negative breast cancers: Biomarkers and outcomes | 4.1 Articoli in Atti di convegno | 2010 | Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia | |
Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; Nair Krishnan, M; Doval Dinesh, C; V. J., Bardou; G., Clark; R., Elledge | |
Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R. | |
HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge | |
The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy. | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; H., Weiss; S., Hilsenbeck; K., Osborne | |
Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy. | 4.1 Articoli in Atti di convegno | 2002 | V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark | |
Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm | |
Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts. | 4.1 Articoli in Atti di convegno | 2006 | M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff | |
Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin | |
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies | 1.5 Abstract in rivista | 2002 | DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco | |
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M. |